表紙
市場調査レポート

Oncodesign SA - 製品パイプライン分析

Oncodesign SA - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 293910
出版日 ページ情報 英文 24 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
Oncodesign SA - 製品パイプライン分析 Oncodesign SA - Product Pipeline Review - 2015
出版日: 2015年02月24日 ページ情報: 英文 24 Pages
概要

Oncodesign はフランスを拠点としたバイオ製薬会社で、癌治療の分野でドラッグディスカバリーおよび薬理学的評価サービスを提供し、特に抗がん治療の前臨床的評価を専門としています。

当レポートでは、Oncodesign SAにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Oncodesign SAの基本情報

Oncodesign SAの概要

  • 主要情報
  • 企業情報

Oncodesign SA:R&Dの概要

  • 主な治療範囲

Oncodesign SA:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Oncodesign SA:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Oncodesign SA:薬剤プロファイル

  • Small Molecules to Inhibit LRRK-2 for Parkinson's Disease
  • Small Molecules to Inhibit Salt-Inducible Kinase 2 for Ovarian Cancer
  • Small Molecules to Inhibit Transforming Growth Factor Beta Receptor II for Cancer
  • Small Molecules to Inhibit Kinase for Neurodegenerative Diseases
  • Small Molecules to Inhibit RIP2 for Crohn's Disease and Polyarthritis

Oncodesign SA:パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

Oncodesign SA:休止中のプロジェクト

Oncodesign SA:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06799CDB

Summary

Global Markets Direct's, 'Oncodesign SA - Product Pipeline Review - 2015', provides an overview of the Oncodesign SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Oncodesign SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Oncodesign SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Oncodesign SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Oncodesign SA's pipeline products

Reasons to buy

  • Evaluate Oncodesign SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Oncodesign SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Oncodesign SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Oncodesign SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Oncodesign SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Oncodesign SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Oncodesign SA Snapshot
    • Oncodesign SA Overview
    • Key Information
    • Key Facts
  • Oncodesign SA - Research and Development Overview
    • Key Therapeutic Areas
    • Oncodesign SA - Pipeline Review
  • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Oncodesign SA - Pipeline Products Glance
    • Oncodesign SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Oncodesign SA - Drug Profiles
    • Small Molecules to Inhibit LRRK-2 for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Salt-Inducible Kinase 2 for Ovarian Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Transforming Growth Factor Beta Receptor II for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Kinase for Neurodegenerative Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit RIP2 for Crohn's Disease and Polyarthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Oncodesign SA - Pipeline Analysis
    • Oncodesign SA - Pipeline Products by Target
    • Oncodesign SA - Pipeline Products by Molecule Type
    • Oncodesign SA - Pipeline Products by Mechanism of Action
  • Oncodesign SA - Dormant Projects
  • Oncodesign SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Oncodesign SA, Key Information
  • Oncodesign SA, Key Facts
  • Oncodesign SA - Pipeline by Indication, 2015
  • Oncodesign SA - Pipeline by Stage of Development, 2015
  • Oncodesign SA - Monotherapy Products in Pipeline, 2015
  • Oncodesign SA - Partnered Products in Pipeline, 2015
  • Oncodesign SA - Partnered Products/ Combination Treatment Modalities, 2015
  • Oncodesign SA - Preclinical, 2015
  • Oncodesign SA - Discovery, 2015
  • Oncodesign SA - Pipeline by Target, 2015
  • Oncodesign SA - Pipeline by Molecule Type, 2015
  • Oncodesign SA - Pipeline Products by Mechanism of Action, 2015
  • Oncodesign SA - Dormant Developmental Projects,2015

List of Figures

  • Oncodesign SA - Pipeline by Top 10 Indication, 2015
  • Oncodesign SA - Pipeline by Stage of Development, 2015
  • Oncodesign SA - Monotherapy Products in Pipeline, 2015
  • Oncodesign SA - Partnered Products in Pipeline, 2015
  • Oncodesign SA - Pipeline by Top 10 Target, 2015
  • Oncodesign SA - Pipeline by Top 10 Molecule Type, 2015
  • Oncodesign SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top